{"id":"https://openalex.org/W2048686497","doi":"https://doi.org/10.1200/jco.2003.12.109","title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","display_name":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","publication_year":2003,"publication_date":"2003-09-30","ids":{"openalex":"https://openalex.org/W2048686497","doi":"https://doi.org/10.1200/jco.2003.12.109","mag":"2048686497","pmid":"https://pubmed.ncbi.nlm.nih.gov/14507946"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2003.12.109","doi":"https://doi.org/10.1200/jco.2003.12.109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2003.12.109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068271757","display_name":"Brian R Leyland-Jones","orcid":"https://orcid.org/0000-0003-2434-0774","observed_orcids":["https://orcid.org/0000-0003-2434-0774"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Brian Leyland-Jones","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067468792","display_name":"Karen A. Gelmon","orcid":"https://orcid.org/0000-0003-4111-2757","observed_orcids":["https://orcid.org/0000-0003-4111-2757"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Karen Gelmon","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111723077","display_name":"Jean-Pierre Ayoub","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Jean-Pierre Ayoub","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049232174","display_name":"Andrew Arnold","orcid":"https://orcid.org/0000-0002-8821-8527","observed_orcids":["https://orcid.org/0000-0002-8821-8527"]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Andrew Arnold","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113553459","display_name":"Shail Verma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Shail Verma","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013717976","display_name":"Reg Dias","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Reg Dias","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5065911796","display_name":"Parviz Ghahramani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1289530486","display_name":"BC Cancer Agency","ror":"https://ror.org/03sfybe47","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1289530486"]},{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Parviz Ghahramani","raw_affiliation_strings":["From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From McGill University, Montreal, Quebec; British Columbia Cancer Agency, Vancouver, British Columbia; Hamilton Regional Cancer Center, Hamilton; Ottawa Regional Cancer Centre, Ottawa; F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada; and F. Hoffmann-La Roche Ltd, Welwyn Garden City, United Kingdom","institution_ids":["https://openalex.org/I1289530486","https://openalex.org/I5023651"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":10.6692,"has_fulltext":false,"cited_by_count":291,"citation_normalized_percentile":{"value":0.99010501,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"21","issue":"21","first_page":"3965","last_page":"3971"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":1.0},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":1.0},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.8849999904632568},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9279999732971191},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5960000157356262},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.7099999785423279},{"id":"https://openalex.org/keywords/cardiotoxicity","display_name":"cardiotoxicity","score":0.7450000047683716},{"id":"https://openalex.org/keywords/infusion-related-reactions","display_name":"infusion reactions","score":0.7039999961853027},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.6309999823570251}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9716030359268188},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.926686704158783},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.6955194473266602},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6825270056724548},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5559499263763428},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4802994132041931},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43818479776382446},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.43269675970077515},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4309746026992798},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.3738807439804077},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3527448773384094}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002170","descriptor_name":"Canada","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015331","descriptor_name":"Cohort Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018734","descriptor_name":"Genes, erbB-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1200/jco.2003.12.109","doi":"https://doi.org/10.1200/jco.2003.12.109","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2003.12.109","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmid:14507946","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/14507946","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","raw_type":"Clinical Trial"},{"id":"mag:2742058787","doi":null,"is_oa":false,"landing_page_url":"https://ascopubs.org/doi/pdf/10.1200/JCO.2003.12.109","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1836239578","https://openalex.org/W1933350662","https://openalex.org/W1970930097","https://openalex.org/W1980184027","https://openalex.org/W1980522495","https://openalex.org/W2006174096","https://openalex.org/W2019229641","https://openalex.org/W2028269517","https://openalex.org/W2029542561","https://openalex.org/W2073871328","https://openalex.org/W2094627540","https://openalex.org/W2095156669","https://openalex.org/W2114974083","https://openalex.org/W2115759102","https://openalex.org/W2141393790","https://openalex.org/W2146406055","https://openalex.org/W2154027407","https://openalex.org/W2156031983","https://openalex.org/W2159305151","https://openalex.org/W2159459001","https://openalex.org/W2222638000","https://openalex.org/W2318605753","https://openalex.org/W2418327139"],"related_works":["https://openalex.org/W2100375606","https://openalex.org/W2348394373","https://openalex.org/W2007855317","https://openalex.org/W2992011999","https://openalex.org/W2028663010","https://openalex.org/W2019035733","https://openalex.org/W2020499692","https://openalex.org/W2303074060","https://openalex.org/W2598807102","https://openalex.org/W2103019840"],"abstract_inverted_index":{"PURPOSE:":[0],"This":[1],"phase":[2],"II":[3],"study":[4],"evaluated":[5],"the":[6,60,100,252],"pharmacokinetics":[7],"and":[8,12,47,127,137,151,160,191,195,210,242],"safety":[9],"of":[10,40,102,107,125,205,221,261],"trastuzumab":[11,41,54,76,108,128,156,222,239,255,262],"paclitaxel":[13,48,64,126],"given":[14],"every":[15,67,78,224],"3":[16,68,79,225],"weeks":[17,69,80,226],"to":[18,111,114,213,267],"women":[19],"with":[20,133,155,231,248,251],"human":[21],"epidermal":[22],"growth":[23],"factor":[24],"receptor":[25],"2":[26],"(HER2)-overexpressing":[27],"metastatic":[28],"breast":[29],"cancer.":[30],"PATIENTS":[31],"AND":[32],"METHODS:":[33],"Thirty-two":[34],"patients":[35,164,197],"received":[36],"a":[37,166],"loading":[38],"dose":[39],"8":[42],"mg/kg":[43,56],"intravenously":[44],"(day":[45,51],"1)":[46],"175":[49,65],"mg/m2":[50,66],"0).":[52],"Thereafter,":[53],"6":[55],"was":[57,81,109,129,187,207,215],"administered":[58,223],"on":[59],"same":[61],"day":[62],"as":[63],"for":[70],"seven":[71,196],"cycles.":[72],"In":[73,229],"responding":[74],"patients,":[75],"monotherapy":[77],"then":[82],"continued":[83],"until":[84],"disease":[85],"progression":[86,214],"or":[87,168],"patient":[88],"withdrawal.":[89],"RESULTS:":[90],"Trastuzumab":[91],"trough":[92,240],"levels":[93,241],"were":[94,146],"more":[95],"than":[96],"20":[97],"mug/mL":[98],"by":[99],"end":[101],"cycle":[103],"1.":[104],"The":[105,123,141,182,202,259],"half-life":[106],"estimated":[110],"be":[112,120],"18":[113],"27":[115],"days,":[116],"although":[117],"this":[118],"may":[119],"an":[121],"underestimate.":[122],"combination":[124,230],"generally":[130,235],"well":[131,236],"tolerated,":[132],"no":[134,138],"unexpected":[135],"toxicities":[136],"pharmacokinetic":[139],"interaction.":[140],"most":[142],"common":[143],"adverse":[144],"events":[145],"myalgia,":[147],"paresthesias,":[148],"alopecia,":[149],"arthralgia,":[150],"fatigue.":[152],"Events":[153],"associated":[154],"included":[157],"infusion-related":[158],"reactions":[159],"cardiac":[161],"dysfunction.":[162],"Ten":[163],"had":[165,178,199],">":[167],"=":[169],"15%":[170],"decrease":[171],"in":[172],"ejection":[173],"fraction,":[174],"but":[175],"only":[176],"one":[177],"symptomatic":[179],"heart":[180],"failure.":[181],"investigator-assessed":[183],"objective":[184],"response":[185,206,244],"rate":[186],"59%":[188],"(four":[189],"complete":[190],"15":[192],"partial":[193],"responses)":[194],"(22%)":[198],"stable":[200],"disease.":[201],"median":[203,211],"duration":[204],"10.5":[208],"months":[209],"time":[212],"12.2":[216],"months.":[217],"CONCLUSION:":[218],"Additional":[219],"investigation":[220],"is":[227,234],"warranted.":[228],"paclitaxel,":[232],"it":[233],"tolerated.":[237],"Plasma":[238],"clinical":[243],"rates":[245],"compare":[246],"favorably":[247],"those":[249],"achieved":[250],"standard":[253],"weekly":[254],"regimen":[256],"plus":[257],"chemotherapy.":[258],"presence":[260],"does":[263],"not":[264],"alter":[265],"exposure":[266],"paclitaxel.":[268]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":7},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":12},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":25},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}